The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...